血小板反應(yīng)蛋白解整合素金屬肽酶7(ADAMTS7)活性蛋白
Active A Disintegrin And Metalloproteinase With Thrombospondin 7 (ADAMTS7)
COMPase
- 編號(hào)UAPB974Mu01
- 物種Mus musculus (Mouse,小鼠) 相同的名稱(chēng),不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)5.8
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 暫無(wú)報(bào)價(jià) 暫無(wú)報(bào)價(jià) 暫無(wú)報(bào)價(jià) 暫無(wú)報(bào)價(jià) 暫無(wú)報(bào)價(jià)
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
活性實(shí)驗(yàn)
A Disintegrin and Metalloproteinase with Thrombospondin 7(ADAMTS7)is a secreted zinc-dependent metalloproteinase belonging to the ADAMTS family, characterized by an N-terminal metalloproteinase domain, disintegrin-like module, and multiple thrombospondin type 1 repeats. Primarily expressed in cardiovascular tissues, skeletal muscle, and cartilage, ADAMTS7 exerts proteolytic functions by cleaving extracellular matrix (ECM) components, such as aggrecan and versican, thereby regulating ECM remodeling. Emerging evidence highlights its critical role in atherosclerosis: it promotes vascular smooth muscle cell (VSMC) migration and proliferation, accelerates plaque formation, and correlates with increased cardiovascular disease risk. Additionally, ADAMTS7 participates in osteoarthritis pathogenesis by degrading cartilage matrix proteins. As a multifunctional protease, it serves as a potential therapeutic target for cardiovascular and musculoskeletal disorders. ADAMTS7 interacts with COMP, likely forming a complex to modulate ECM homeostasis and tissue remodeling processes.Thus a functional ELISA assay was conducted to detect the interaction of recombinant mouse ADAMTS7 and recombinant rat COMP. Briefly, ADAMTS7 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to COMP-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-ADAMTS7 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant mouse ADAMTS7 and recombinant rat COMP was shown in Figure 1, the EC50?for this effect is 0.193μg/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
| UAPB974Mu01 | 血小板反應(yīng)蛋白解整合素金屬肽酶7(ADAMTS7)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPB974Mu01 | 血小板反應(yīng)蛋白解整合素金屬肽酶7(ADAMTS7)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB974Mu01 | 血小板反應(yīng)蛋白解整合素金屬肽酶7(ADAMTS7)多克隆抗體 | IHC |
| ULAB974Mu81 | 血小板反應(yīng)蛋白解整合素金屬肽酶7(ADAMTS7)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| ULAB974Mu71 | 血小板反應(yīng)蛋白解整合素金屬肽酶7(ADAMTS7)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Int Wound J. | From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases. [Pubmed:26991748] |
| Cell Physiol Biochem. | Association of ADAMTS-7 Levels with Cardiac Function in a Rat Model of Acute Myocardial Infarction [Pubmed:26938210] |
| Medicine (Baltimore) | Association between plasma ADAMTS-7 levels and severity of disease in patients with stable obstructive coronary artery disease [pubmed:27902619] |
| International Wound Journal | From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases [pubmed:26991748] |
| Atherosclerosis | Association of serum ADAMTS7 levels and genetic variant rs1994016 with acute coronary syndrome in a Chinese population: A case control study [Pubmed:29980058] |

